Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer?

Affiliations

Comment

Eila Skinner. Nat Clin Pract Urol. 2007 May.

. 2007 May;4(5):248-9.

doi: 10.1038/ncpuro0762. Epub 2007 Mar 27.

¹ Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. skinner@usc.edu

No abstract available

Comment on

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA. van der Heijden AG, et al. J Urol. 2006 Oct;176(4 Pt 1):1349-53; discussion 1353. doi: 10.1016/j.juro.2006.06.007. J Urol. 2006. PMID: 16952629 Clinical Trial.